What to do with a rising PSA after complete remission post-prostatectomy?;Conduite à tenir devant une ascension du PSA après rémission complète postprostatectomie ?

Cancer/Radiotherapie

Volumn 10, Issue 4, 2006, Pages 168-174

  Bosset, M ^a   Bosset, J F ^b   Maingon, P ^a  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Biological relapse; Prostatic carcinoma; Treatment strategy

Indexed keywords

ANTINEOPLASTIC AGENT; HORMONE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

CANCER COMBINATION CHEMOTHERAPY; HORMONAL THERAPY; HUMAN; LIFE EXPECTANCY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; TREATMENT FAILURE; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; MALE; PROSTATE TUMOR; REMISSION; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 33746264930     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2006.01.004     Document Type: Short Survey

References (46)

1. Anaes, groupe de travail. Éléments d'information des hommes envisageant la réalisation d'un dépistage individuel du cancer de prostate septembre 2004.
2. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 369-375
3. Astro. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology consensus panel. Int. J. Radiat. Oncol. Biol. Phys. 156 (1997) 1035-1041
4. Bolla M, Van Poppel P, Van Caugh P, Vekemans K, Rigatti P, et al. Does post-operative radiotherapy after radical prostatectomy improve progression free survival in pT3N0 prostate cancer? (EORTC 22911). 2004 ASCO Annual Meeting Abstract 4504.
5. Bourguet P., and Groupe de travail SOR. Standards, options et recommandations : utilisations du FDG-PET en cancérologie. Résultats dans les cancers urologiques. Bull. Cancer 90 (2003) S80-S87 (Spec No :)
6. Cadeddu J.A., Partin A.W., De Weese T.L., and Walsh P.C. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J. Urol. 159 (1998) 173-177
7. Chang C.H., Wu H.C., Tsai J.J., Shen Y.Y., Changlai S.P., and Kao A. Detecting metastatic pelvic lymphe nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol. Int. 70 4 (2003) 311-315
8. Cher M.L., Bianco Jr. F.J., and Lam J.S. Limited role of radionuclide bone scintigraphy in patients with prostate spacific antigen elevations after radicalprostatectomy. Radiother. Oncol. 59 (2001) 51-60
9. Comité de cancérologie de l'Association française d'urologie recommandations 2002. Prog. Urol. 2002; 12.
10. D'amico A., Whittington R., Malkowickz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, extern beam radiotherapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
11. D'amico A., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 35 (2004) 125-135
12. Do T., Parker R.G., Do C., Tran L., Do L., and Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J. Sci. Am. 4 (1998) 324-330
13. Freedland S.J., Presti J.C., Amling C.L., Kane C.J., Dorey F., and Terris M.K. Time trends in biochemical recurrence after radical prostatectomy: results of the search database. Urology 61 4 (2003) 742-747
14. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determinig PSA recurrence after radical prostatectomy. Urology 61 2 (2003) 365-369
15. Garg M.K., Tekyi-Mensah S., Bolton S., Velasco J., Pontes E., Wood Jr. D.P., et al. Impact of postprostatectomy prostate-specific antigen Nadir on outcomes following salvage radiotherapy. Urology 51 (1998) 998-1002
16. Haab F., Meulenas A., Ravery V., and Boccon-Gibod L. L'antigène spécifique de la prostate : applications cliniques du dosage ultrasensible. Presse Med. 24 (1995) 36
17. Haese A., Huland E., Graefen M., Hammer P., Noldus J., and Huland H. Ultrasensitive detection of prostate specific antigen in the follow up of 422 patients after radical prostatectomy. J. Urol. 161 4 (1999) 1206-1211
18. Hagan M., and Zlotecki R. Comparison of adjuvant versus salvage radiotherapy policies for prostatectomy radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 329-340
19. Hanks G.E., Hanlon A.L., Lee W.R., Slivjak A., and Schulteiss T.E. Pretreatment prostate-specific antigen doubling times: clinical utiity of this predictor of prostate cancer behavior. Int. J. Radiat. Oncol. Biol. Phys. 34 3 (1996) 549-553
20. Hennequin C., Ravery V., Maylin C., and Boccon-Gibbod L. Radiothérapie postprostatectomie : pour quels patients et quand ?. Cancer Radiother. 6 (2002) 168-174
21. Hofer C., Laubenbacher C., Block T., Breul J., Hartung R., and Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomographic useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 36 1 (1999) 31-35
22. Jhaveri F., and Klein E. How to explore the patient with a rising PSA after radical prostatectomy; defining local vs systemic failure. Sem. Urol. Oncol. 17 (1999) 130-134
23. Johnstone P.A.S., and Riffenburgh R. Yeald of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol. Oncol. 3 (1997) 108-112
24. Kahn D., Williams R.D., and Haseman M.K. Radioimmunoscintigraphy with In-11-labelled capromad pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin. Oncol. 16 (1998) 284-289
25. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative normogram for disease recurence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 17 (1999) 1499-1507
26. Katz M.S., Zelefsky M.J., Venkatrauan E.S., Fuks Z., Hummer A., and Leibel S.A. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J. Clin. Oncol. 21 (2003) 483-489
27. King C.R., Presti J.C., Gill K., Brooks J., and Hancock S.L. Radiotherapy after radical prostatectomy: does transient anrogen improve outcome?. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 341-347
28. Leventis A.K., Shariat S.F., Kattan M.W., Butler E.B., Wheeler T.M., and Slawin K.M. Prediction of reponse to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 19 (2001) 1030-1039
29. Levesque P.E., Nieh P.T., Zinman L.N., Seldin D.W., and Libertino J.A. Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrence carcinoma after prostatectomy. Urology 51 (1998) 978-984
30. Macdonald O.K., Schild S.E., Vora S.A., Andrews P.E., Ferrigni R.G., Novichi D.E., et al. Salvage radiotherapy for palpable locally recurrent prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004) 1530-1538
31. Oyama N., Miller T.R., Dehdashti F., Siegel B.A., Fisher K.C., Michalski T.M., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J. Nucl. Med. 44 4 (2003) 549-555
32. Pisansky T.M., Kozelsky T.F., and Myers R.P. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 163 (2000) 845-850
33. Pound C.R., Partin A.W., Epstein J.I., and Walsh P.C. Prostate specific antigen after radical retropubic prostatectomy patterns of recurrence and cancer control. Urol. Clin. North. Am. 24 (1997) 395-406
34. Pound C.R., Partin A.W., Eisenberg M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy for prostate cancer. Am. Med. Assoc. 281 (1999) 1591-1597
35. Prestigiacomo A.F., and Stamey T.A. A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after prostectomy. J. Urol. 152 (1994) 1515-1519
36. Salomon C.G., Flisak M.E., Olson M.C., Dudiak C.M., Flamigan R.C., and Waters W.B. Radical prostatectomy: transrectal sonographic evaluation to assess for local recurrence. Radiology 189 (1993) 713-719
37. See W.A., Wirth M.P., Mc Leod D.G., Iversen P., Klimberg I., Gleason D., et al. Casodex early Prostate Trialist Group Bicalutamide as immediate therapy either alone or as adjuvant standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol. 168 2 (2002) 429-435
38. Seltzer M., Barbaric Z., Belldegrun A., Naitoh J., Dorey F., Phelps M.B., et al. Comparison of coputed tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 162 4 (1999) 1322-1328
39. Shingal R., Yemoto C., Mc Neal J.E., and Brooks J.D. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Urology 61 2 (2003) 380-385
40. Song D.Y., Thompson T.L., Ramakrishnan V., Harrison R., Bhavsar N., Onaodowan O., et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60 (2002) 281-287
41. Takayama T.K., Vessela R.L., Brawer M.K., Noteboom J., and Lange P.H. The enhanced detection of persistent disease after prostatectomy with a new prostate specific antigen immunoassay. J. Urol. 150 (1993) 374-378
42. Valicenti R.K., Gomella L.G., Perez, and CA. Radiation therapy after radical prostatectomy: a review of the issues and options. Sem. Rad Oncol. 13 (2003) 130-140
43. Vicini F.A., Ziaja E., Kestin L.L., Brabbins D.S., Stromberg J.S., Gonzales J.A., et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate. Cancer Urol. 54 (1999) 111-117
44. Wirth M.P., William A.S., McLeod D.G., Iversen P., Morris T., and Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median follow up of 5,4 years. J. Urol. 172 (2004) 1865-1870
45. Wu J.J., King S.C., Montana G.S., Mc Kinstry C.A., and Anscher M.S. The efficacy of prostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int. J. Radiat. Oncol. Biol. Phys. 32 (1995) 317-323
46. Zelefsky M.J., Aschenasy E., Kelsen S., and Leibel S.A. Tolerance and early outcome results of prostatectomy three dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 39 (1997) 327-333